Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Other Non Operating Income (2023)

Updated

Radiopharm Theranostics (RADX) reported Other Non Operating Income of $72,904 for FY2026 (year ended Jun 30, 2026), up 11.0% from $65,688 in FY2025.

Analysis

Radiopharm Theranostics (RADX) Other Non Operating Income (2023) Analysis & Trends

  • According to Business Quant data, Other Non Operating Income came in at $65,688 in FY2025 (+642.1%) and $8,851 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 -257,251.00
API Access

Radiopharm Theranostics Other Non Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-operating-income&ticker=RADX&period=max&api_key=YOUR_API_KEY